Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133(+) bone marrow stem cell transplant - PubMed (original) (raw)
Randomized Controlled Trial
. 2011 Dec;142(6):1530-9.e3.
doi: 10.1016/j.jtcvs.2011.05.002. Epub 2011 Jun 12.
Affiliations
- PMID: 21664627
- DOI: 10.1016/j.jtcvs.2011.05.002
Free article
Randomized Controlled Trial
Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133(+) bone marrow stem cell transplant
Can Yerebakan et al. J Thorac Cardiovasc Surg. 2011 Dec.
Free article
Abstract
Objective: Our objective was to elucidate long-term clinical and functional effects of intramyocardial stem cell transplant and to identify patients who will show sustained benefit.
Methods: Long-term outcomes of 35 patients after intramyocardial CD133(+) bone marrow stem cell transplant during coronary artery bypass grafting were compared with those of a control group of 20 patients after coronary artery bypass grafting alone. Clinical effects were assessed with the New York Heart Association classification system and the Minnesota Living With Heart Failure questionnaire. Electrocardiography, 24-hour Holter monitoring, echocardiography, myocardial perfusion scanning, magnetic resonance imaging, and computed tomography were performed. Logistic regression analyses were used to identify prognostic factors for improvement in long-term left ventricular ejection fraction after stem cell treatment.
Results: The stem cell group revealed similar New York Heart Association and life quality scores to the control group. Myocardial perfusion score at the area of risk was significantly increased in the stem cell group after 36-month follow-up (P = .024 vs control). Multivariate logistic regression analysis revealed a 44-fold higher probability of at least 5% improvement in left ventricular ejection fraction for patients with preoperative left ventricular ejection fraction not greater than 40% than for patients with preoperative ejection fraction greater than 40% (P = .018). Furthermore, patients operated on between 7 and 12 weeks after myocardial infarction had a 56-fold higher chance of at least 5% improvement in left ventricular ejection fraction than patients treated later than 12 weeks after infarction (P = .023).
Conclusions: Intramyocardial stem cell therapy was safe but lacked significant lasting benefits beyond 6 months in our study cohort with a limited number of patients. Preoperative left ventricular ejection fraction and time since myocardial infarction may be critical parameters for selection of patients who can benefit most from intramyocardial stem cell treatment during coronary artery bypass grafting.
Copyright © 2011 The American Association for Thoracic Surgery. All rights reserved.
Similar articles
- Pilot study to evaluate the safety and feasibility of intracoronary CD133(+) and CD133(-) CD34(+) cell therapy in patients with nonviable anterior myocardial infarction.
Manginas A, Goussetis E, Koutelou M, Karatasakis G, Peristeri I, Theodorakos A, Leontiadis E, Plessas N, Theodosaki M, Graphakos S, Cokkinos DV. Manginas A, et al. Catheter Cardiovasc Interv. 2007 May 1;69(6):773-81. doi: 10.1002/ccd.21023. Catheter Cardiovasc Interv. 2007. PMID: 17394248 Clinical Trial. - Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial.
Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, Knosalla C, Choi YH, Hetzer R, Stamm C. Nasseri BA, et al. Eur Heart J. 2014 May 14;35(19):1263-74. doi: 10.1093/eurheartj/ehu007. Epub 2014 Feb 3. Eur Heart J. 2014. PMID: 24497345 Clinical Trial. - Five-year follow-up of the local autologous transplantation of CD133+ enriched bone marrow cells in patients with myocardial infarction.
Ahmadi H, Farahani MM, Kouhkan A, Moazzami K, Fazeli R, Sadeghian H, Namiri M, Madani-Civi M, Baharvand H, Aghdami N. Ahmadi H, et al. Arch Iran Med. 2012 Jan;15(1):32-5. Arch Iran Med. 2012. PMID: 22208441 - Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: a meta-analysis.
Donndorf P, Kundt G, Kaminski A, Yerebakan C, Liebold A, Steinhoff G, Glass A. Donndorf P, et al. J Thorac Cardiovasc Surg. 2011 Oct;142(4):911-20. doi: 10.1016/j.jtcvs.2010.12.013. Epub 2011 Mar 3. J Thorac Cardiovasc Surg. 2011. PMID: 21376346 Review. - Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results.
Pompilio G, Steinhoff G, Liebold A, Pesce M, Alamanni F, Capogrossi MC, Biglioli P. Pompilio G, et al. Thorac Cardiovasc Surg. 2008 Mar;56(2):71-6. doi: 10.1055/s-2007-989351. Thorac Cardiovasc Surg. 2008. PMID: 18278680 Review.
Cited by
- Regenerating Damaged Myocardium: A Review of Stem-Cell Therapies for Heart Failure.
Fan D, Wu H, Pan K, Peng H, Wu R. Fan D, et al. Cells. 2021 Nov 11;10(11):3125. doi: 10.3390/cells10113125. Cells. 2021. PMID: 34831347 Free PMC article. Review. - COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial.
Naseri MH, Madani H, Ahmadi Tafti SH, Moshkani Farahani M, Kazemi Saleh D, Hosseinnejad H, Hosseini S, Hekmat S, Hossein Ahmadi Z, Dehghani M, Saadat A, Mardpour S, Hosseini SE, Esmaeilzadeh M, Sadeghian H, Bahoush G, Bassi A, Amin A, Fazeli R, Sharafi Y, Arab L, Movahhed M, Davaran S, Ramezanzadeh N, Kouhkan A, Hezavehei A, Namiri M, Kashfi F, Akhlaghi A, Sotoodehnejadnematalahi F, Vosough Dizaji A, Gourabi H, Syedi N, Shahverdi AH, Baharvand H, Aghdami N. Naseri MH, et al. Cell J. 2018 Jul;20(2):267-277. doi: 10.22074/cellj.2018.5197. Epub 2018 Mar 18. Cell J. 2018. PMID: 29633605 Free PMC article. - Stem cell transplantation dose in patients with acute myocardial infarction: A meta-analysis.
Xu JY, Cai WY, Tian M, Liu D, Huang RC. Xu JY, et al. Chronic Dis Transl Med. 2016 Nov 9;2(2):92-101. doi: 10.1016/j.cdtm.2016.09.006. eCollection 2016 Jun. Chronic Dis Transl Med. 2016. PMID: 29063029 Free PMC article. - A new methodological sequence to expand and transdifferentiate human umbilical cord blood derived CD133+ cells into a cardiomyocyte-like phenotype.
Cui YX, Kafienah W, Suleiman MS, Ascione R. Cui YX, et al. Stem Cell Rev Rep. 2013 Jun;9(3):350-9. doi: 10.1007/s12015-011-9316-9. Stem Cell Rev Rep. 2013. PMID: 21948151 - Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis.
Lee SH, Hong JH, Cho KH, Noh JW, Cho HJ. Lee SH, et al. Stem Cell Res Ther. 2016 Oct 20;7(1):153. doi: 10.1186/s13287-016-0415-z. Stem Cell Res Ther. 2016. PMID: 27765070 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials